Limits...
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.

Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski CC - Cancer Sci. (2014)

Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.

View Article: PubMed Central - PubMed

Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier estimates for overall survival in patients with metastatic colorectal cancer treated with bevacizumab, grouped according to baseline serum carcinoembryonic antigen (CEA) level (CEA ≤26.8 ng/mL vs CEA >26.8 ng/mL).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317865&req=5

fig03: Kaplan–Meier estimates for overall survival in patients with metastatic colorectal cancer treated with bevacizumab, grouped according to baseline serum carcinoembryonic antigen (CEA) level (CEA ≤26.8 ng/mL vs CEA >26.8 ng/mL).

Mentions: Median OS was 37.5 months in group I and 21.4 months in group II (P = 0.019). The survival rates at 24 months were 62% (95% CI, 51–75%) and 43% (95% CI, 32–58%), respectively (Fig. 3a). The HR of group II versus group I was 1.71 (1.08–2.70). This HR was virtually unchanged if adjusted for T and N (HR, 1.78; 95% CI, 1.11–2.85).


Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.

Prager GW, Braemswig KH, Martel A, Unseld M, Heinze G, Brodowicz T, Scheithauer W, Kornek G, Zielinski CC - Cancer Sci. (2014)

Kaplan–Meier estimates for overall survival in patients with metastatic colorectal cancer treated with bevacizumab, grouped according to baseline serum carcinoembryonic antigen (CEA) level (CEA ≤26.8 ng/mL vs CEA >26.8 ng/mL).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317865&req=5

fig03: Kaplan–Meier estimates for overall survival in patients with metastatic colorectal cancer treated with bevacizumab, grouped according to baseline serum carcinoembryonic antigen (CEA) level (CEA ≤26.8 ng/mL vs CEA >26.8 ng/mL).
Mentions: Median OS was 37.5 months in group I and 21.4 months in group II (P = 0.019). The survival rates at 24 months were 62% (95% CI, 51–75%) and 43% (95% CI, 32–58%), respectively (Fig. 3a). The HR of group II versus group I was 1.71 (1.08–2.70). This HR was virtually unchanged if adjusted for T and N (HR, 1.78; 95% CI, 1.11–2.85).

Bottom Line: Patients with baseline CEA serum levels below the statistical median of 26.8 ng/mL (group I) were compared with patients with higher CEA levels (group II).The cetuximab-based treatment cohort was analyzed for specificity assessment of CEA to predict the anti-vascular endothelial growth factor effect in mCRC.In an independent cohort of 129 patients treated with cetuximab-based therapy, no association of therapeutic response or PFS with CEA serum levels was found.

View Article: PubMed Central - PubMed

Affiliation: Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Austria.

Show MeSH
Related in: MedlinePlus